HGBP-1 Expression Predicts Shorter Progression-Free Survival in Ovarian Cancers, While Contributing to Paclitaxel Resistance

Overview

Journal J Cancer Ther

Date 2017 Jan 17

PMID 28090373

Citations 13

Authors

Suzan Wadi

Aaron R Tipton

Jill A Trendel

Sadik A Khuder

Deborah J Vestal

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is the gynecological cancer with the poorest prognosis. One significant reason is the development of resistance to the chemotherapeutic drugs used in its treatment. The large GTPase, hGBP-1, has been implicated in paclitaxel resistance in ovarian cell lines. Forced expression of hGBP-1 in SKOV3 ovarian cancer cells protects them from paclitaxel-induced cell death. However, prior to this study, nothing was known about whether hGBP-1 was expressed in ovarian tumors and whether its expression correlated with paclitaxel resistance. hGBP-1 is expressed in 17% of ovarian tumors from patients that have not yet received treatment. However, at least 80% of the ovarian tumors that recurred after therapies that included a tax-ane, either paclitaxel or docetaxel, were positive for hGBP-1. In addition, hGBP-1 expression predicts a significantly shorter progression-free survival in ovarian cancers. Based on these studies, hGBP-1 could prove to be a potential biomarker for paclitaxel resistance in ovarian cancer.

Citing Articles

Role of guanylate-binding protein 1 in the proliferation of invasive lung adenocarcinoma cells.

Kumada T, Mimae T, Tsubokawa N, Kushitani K, Takeshima Y, Miyata Y Front Oncol. 2025; 15:1434249.

PMID: 40018406 PMC: 11865198. DOI: 10.3389/fonc.2025.1434249.

The Large GTPase Guanylate-Binding Protein-1 (GBP-1) Promotes Mitochondrial Fission in Glioblastoma.

Kalb R, Nyabuto G, Morran M, Maity S, Justinger J, Nestor-Kalinoski A Int J Mol Sci. 2024; 25(20).

PMID: 39457021 PMC: 11508455. DOI: 10.3390/ijms252011236.

DNA hypo-methylation and expression of GBP4 induces T cell exhaustion in pancreatic cancer.

Tasiheng Y, Lin X, Zou X, Chen Y, Yan Y, Ma M Cancer Immunol Immunother. 2024; 73(10):208.

PMID: 39110249 PMC: 11306721. DOI: 10.1007/s00262-024-03786-3.

Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers.

Liao H, Chen X, Wang H, Lin Y, Chen L, Yuan K Cancer Res. 2024; 84(11):1747-1763.

PMID: 38471085 PMC: 11148548. DOI: 10.1158/0008-5472.CAN-23-3298.

The role of interferons in ovarian cancer progression: Hinderer or promoter?.

Liu T, Li Y, Wang X, Yang X, Fu Y, Zheng Y Front Immunol. 2023; 13:1087620.

PMID: 36618371 PMC: 9810991. DOI: 10.3389/fimmu.2022.1087620.

References

Gorbacheva V, Lindner D, Sen G, Vestal D . The interferon (IFN)-induced GTPase, mGBP-2. Role in IFN-gamma-induced murine fibroblast proliferation. J Biol Chem. 2001; 277(8):6080-7. DOI: 10.1074/jbc.M110542200. View

Aguirre E, Renner O, Narlik-Grassow M, Blanco-Aparicio C . Genetic Modeling of PIM Proteins in Cancer: Proviral Tagging and Cooperation with Oncogenes, Tumor Suppressor Genes, and Carcinogens. Front Oncol. 2014; 4:109. PMC: 4030178. DOI: 10.3389/fonc.2014.00109. View

Persico M, Petrella L, Orteca N, Dato A, Mariani M, Andreoli M . GTP is an allosteric modulator of the interaction between the guanylate-binding protein 1 and the prosurvival kinase PIM1. Eur J Med Chem. 2014; 91:132-44. DOI: 10.1016/j.ejmech.2014.07.093. View

Yu C, Chang K, Chang Y, Hsu C, Liang Y, Yu J . Identification of guanylate-binding protein 1 as a potential oral cancer marker involved in cell invasion using omics-based analysis. J Proteome Res. 2011; 10(8):3778-88. DOI: 10.1021/pr2004133. View

Andreoli M, Persico M, Kumar A, Orteca N, Kumar V, Pepe A . Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells. J Med Chem. 2014; 57(19):7916-32. PMC: 4191604. DOI: 10.1021/jm5009902. View

Duan Z, Foster R, Brakora K, Yusuf R, Seiden M . GBP1 overexpression is associated with a paclitaxel resistance phenotype. Cancer Chemother Pharmacol. 2005; 57(1):25-33. DOI: 10.1007/s00280-005-0026-3. View

Vestal D, Jeyaratnam J . The guanylate-binding proteins: emerging insights into the biochemical properties and functions of this family of large interferon-induced guanosine triphosphatase. J Interferon Cytokine Res. 2010; 31(1):89-97. PMC: 3021356. DOI: 10.1089/jir.2010.0102. View

Naschberger E, Croner R, Merkel S, Dimmler A, Tripal P, Amann K . Angiostatic immune reaction in colorectal carcinoma: Impact on survival and perspectives for antiangiogenic therapy. Int J Cancer. 2008; 123(9):2120-9. DOI: 10.1002/ijc.23764. View

De Donato M, Mariani M, Petrella L, Martinelli E, Zannoni G, Vellone V . Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol. 2011; 227(3):1034-41. DOI: 10.1002/jcp.22813. View

10.

Britzen-Laurent N, Lipnik K, Ocker M, Naschberger E, Schellerer V, Croner R . GBP-1 acts as a tumor suppressor in colorectal cancer cells. Carcinogenesis. 2012; 34(1):153-62. DOI: 10.1093/carcin/bgs310. View

11.

Duan Z, Lamendola D, Duan Y, Yusuf R, Seiden M . Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol. 2004; 55(3):277-85. DOI: 10.1007/s00280-004-0878-y. View

12.

Ascierto M, Kmieciak M, Idowu M, Manjili R, Zhao Y, Grimes M . A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat. 2011; 131(3):871-80. PMC: 3431022. DOI: 10.1007/s10549-011-1470-x. View

13.

Tipton A, Nyabuto G, Trendel J, Mazur T, Wilson J, Wadi S . Guanylate-Binding Protein-1 protects ovarian cancer cell lines but not breast cancer cell lines from killing by paclitaxel. Biochem Biophys Res Commun. 2016; 478(4):1617-23. PMC: 5030188. DOI: 10.1016/j.bbrc.2016.08.169. View

14.

Gyorffy B, Lanczky A, Szallasi Z . Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012; 19(2):197-208. DOI: 10.1530/ERC-11-0329. View

15.

Messmer-Blust A, Balasubramanian S, Gorbacheva V, Jeyaratnam J, Vestal D . The interferon-gamma-induced murine guanylate-binding protein-2 inhibits rac activation during cell spreading on fibronectin and after platelet-derived growth factor treatment: role for phosphatidylinositol 3-kinase. Mol Biol Cell. 2010; 21(14):2514-28. PMC: 2903678. DOI: 10.1091/mbc.e09-04-0344. View

16.

Johnson H, Del Rosario A, Bryson B, Schroeder M, Sarkaria J, White F . Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts. Mol Cell Proteomics. 2012; 11(12):1724-40. PMC: 3518138. DOI: 10.1074/mcp.M112.019984. View

17.

Gyorffy B, Lanczky A, Eklund A, Denkert C, Budczies J, Li Q . An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2009; 123(3):725-31. DOI: 10.1007/s10549-009-0674-9. View